In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 301 to 325 of 389

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Sacituzumab govitecan with pembrolizumab for untreated metastatic non-small-cell lung cancer with a PD-L1 expression of 50% or more [ID6739]	Technology appraisal guidance	TBC
Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer untreated with BCG [ID6454]	Technology appraisal guidance	TBC
School-based interventions: physical and mental health and wellbeing promotion	Quality standard	TBC
Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over [ID6284]	Technology appraisal guidance	TBC
Secukinumab for treating giant cell arteritis in people 50 years and over [ID6563]	Technology appraisal guidance	TBC
Seladelpar for previously treated primary biliary cholangitis [ID6429]	Technology appraisal guidance	TBC
Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options [ID6273]	Technology appraisal guidance	TBC
Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]	Technology appraisal guidance	TBC
Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 [ID6385]	Technology appraisal guidance	TBC
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity [ID6441]	Technology appraisal guidance	14 May 2026
Semaglutide for treating moderate to advanced liver fibrosis (without cirrhosis) caused by metabolic dysfunction-associated steatohepatitis [ID6458]	Technology appraisal guidance	TBC
Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [ID6346]	Technology appraisal guidance	TBC
Setmelanotide for treating acquired hypothalamic obesity in people 4 years and over [ID6542]	Technology appraisal guidance	10 February 2027
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome (review of HST31) [ID6598]	Highly specialised technology	19 August 2026
Severe and enduring mental illness guidance review	NICE guideline	TBC
Sipavibart for preventing COVID 19 [ID6282]	Technology appraisal guidance	TBC
Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6440]	Technology appraisal guidance	TBC
Sirolimus-eluting collagen implant for creating vascular access for haemodialysis in end-stage kidney disease [TSID9147]	Technology appraisal guidance	TBC
Sodium zirconium cyclosilicate for treating hyperkalaemia (partial review of TA599) [ID6439]	Technology appraisal guidance	TBC
Software for electroencephalogram (EEG) interpretation to support diagnosing epilepsy	Health technology evaluation	15 September 2026
Sonrotoclax for treating relapsed or refractory mantle cell lymphoma after an anti-CD20 treatment and a BTK inhibitor [ID6654]	Technology appraisal guidance	TBC
Sotatercept for treating pulmonary arterial hypertension [ID6163]	Technology appraisal guidance	TBC
Soticlestat for treating seizures associated with Dravet syndrome in people 2 years and over [TSID12091]	Technology appraisal guidance	TBC
Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [TSID10632]	Technology appraisal guidance	TBC
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287]	Technology appraisal guidance	TBC

Results per page

10
25
50
All